Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Towards rational prescribing of antibiotics for acute rhinosinusitis: evaluation of the impact and costs of implementation strategies based on a multidisciplinary evidence-based guideline
ISRCTN ISRCTN57375471
ClinicalTrials.gov identifier
Public title Towards rational prescribing of antibiotics for acute rhinosinusitis: evaluation of the impact and costs of implementation strategies based on a multidisciplinary evidence-based guideline
Scientific title
Acronym N/A
Serial number at source F6/12 - AV - F 681
Study hypothesis In Belgium consumption of antibiotics is among the highest in Europe. As a result antimicrobial resistance rates are alarming. Recently a number of evidence-based guidelines on rational use of antibiotics have been produced and disseminated by the scientific organisations in collaboration with the Belgian Co-ordinating Committee for Antibiotic Policy. International research has shown that merely distributing guidelines to professionals in the field does not lead to behaviour change. In Belgium several strategies for implementation of good clinical practice, i.e. local peer review groups and academic detailing, have been initiated. However, the (local) effectiveness and cost-effectiveness of these strategies has not been evaluated. This project will investigate the impact of each of the strategies separately and the combination of both strategies in general practice, following the publication of a guideline on the management of acute rhinosinusitis. This guideline aims at rationalizing (i.e. reducing) the prescription rate for this condition in primary care.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Belgium
Disease/condition/study domain Implementation of a practice guideline for acute rhinosinusitis in general practice
Participants - inclusion criteria Local peer review groups of general practitioners in Flanders, Belgium (approximately 10-20 GPs per group) are invited to participate.
Participants - exclusion criteria Groups that have participated in the field testing of the guideline, groups that have been visited by academic detailers more than once in the past, groups located at >1 hour drive from the study centres.
Anticipated start date 01/07/2004
Anticipated end date 30/06/2005
Status of trial Completed
Patient information material
Target number of participants 135 patient registrations are aimed for in each study arm
Interventions Cluster randomised factorial trial with 4 study arms.
Interventions: academic detailing visits to individual GPs and/or group sessions of GPs on the key messages of the guideline.
Control: no specific intervention
Primary outcome measure(s) Antibiotic prescription rate, cost-effectiveness.
Secondary outcome measure(s) Choice of antibiotic, use of personalized non-drug prescriptions, clinical course of rhinosinusitis as reported in patient diaries.
Sources of funding Federal Belgian Ministry of Health and Fund for Scientific Research Flanders, Dossier nr. G.0617.05
Trial website
Publications Results: http://www.ncbi.nlm.nih.gov/pubmed/17545346
Contact name Prof  Marc  De Meyere
  Address De Pintelaan 185 1K3
  City/town Ghent
  Zip/Postcode B-9000
  Country Belgium
  Email marc.demeyere@ugent.be
Sponsor Fund for Scientific Research, Flanders (Belgium)
  Address Egmontstraat 5
  City/town Brussels
  Zip/Postcode B-1000
  Country Belgium
Date applied 18/03/2005
Last edited 15/04/2008
Date ISRCTN assigned 25/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central